Objective: The mechanism of biological treatment molecule called omalizumab used in asthma treatment is thought to be versatile; however, the mechanism still remains unknown. This study was undertaken in severe asthma patients underwent omalizumab treatment, in order to investigate the relationship between biomarker expression and disease characteristics related to the immune system.
INTRODUCTION
Allergic asthma is a disease which mostly exists at the Mediterranean coast (1) . Furthermore, previous studies engaged in the relationship between climate records and the disease stated that the number of patients visiting the clinic with increased health problems has increased with the increasing amount of pollen in the air (2) . During the recent years, anti-immunoglobulin E (IgE) therapy (omalizumab) has been developed as a primary representative of new therapeutic class for allergic asthma and has become a crucial example for the biological treatments (3) . Important guidelines for asthma, such as the Global Initiative for Asthma (GINA) and National Asthma Education and Prevention Expert Panel Report 3 (EPR-3), stated omalizumab can be used for severe asthma patients (4, 5) .
The mechanism of action of anti-IgE has a decreasing effect on the free IgE and afterwards decreases the regulatory effect on the IgE receptors of basophils and mast cells. Hence, inhaled allergen reac-tions are diminished (6) . Throughout the regression, mast cell concerned effects are decreased, and mediators linking with the symptoms of patients with allergies and asthma are released. Besides, the reduction of allergic inflammation is also associated to the rush of eosinophilic granulocytes (7).
Among the later described molecules in serum which have a regulatory effect on inflammation and immune reactivity, homocysteine (Hcy), 25-hydroxyvitamin D (25(OH)D), eosinophil cationic peptide (ECP), interleukin-1 β (IL-1β), and OX2 (sCD200) are more focused on. Already existing studies suggest that OX2 and its receptor OX2R interactions regulate the allergic inflammatory disease that IL-1β has important effects on the inflammation of the respiratory tract, and that increased ECP levels are correlated with asthma exacerbation (8, 9) . Moreover, 25(OH)D activates an Hcy-metabolizing enzyme. A significant study suggested a correlation between vitamin D status and Hcy levels (10) . Some studies revealed that Hcy has an effect on inflammatory cytokine/chemokine production and it might be through monocytes and macrophages in serum (11, 12) . Therefore, Hcy appears to have immunomodulating and pro-inflammatory activities.
As little is known about the potential relationship between all these inflammatory markers, the objective of our study is to consider the potential impact of immunomodulation related with biomolecules of Hcy, ECP, 25(OH)D, IL-1β, and OX2 concentrations together with clinical markers of fractional exhaled nitric oxide (FeNO), asthma control test (ACT), and pulmonary function tests in asthmatic patients who is undergoing the biological treatment of omalizumab.
METHODS

Subjects
Consecutive patients with severe asthma disease (n=15, Group I) without any other autoimmune and/or chronic disorders, older than 18 years, managed by the Clinical Immunology and Allergy Unit, were recruited for the study. Age-and sex-matched control group (n=25, Group II) was diagnosed to have any atopy, autoimmune disorder, or allergic disease and major systemic disorders attending the outpatient of the same clinic. None of the participants smoked cigarette. They were informed about the study and were asked for consent before starting the study. The study had local Ethical Committee approval.
Laboratory
In Group I, 7 males and 8 females were diagnosed with severe allergic asthma and allergic rhinitis. They all underwent omalizumab treatment with 300-375 IU/mL subcutaneous injection within every 2 weeks for 12 months. Serum specimens were collected in May, which is the highest air pollination period in our region when they were first diagnosed and were named as Group IA (pre-omalizumab), and after 12 months of treatment during the disease remission as Group IB (post-omalizumab) (1, 2) . All the samples for serum soluble markers' evaluation were collected at approximately 8-10 AM. As a result of the effects on inflammatory markers, participants abstained from caffeinated drinks and food for 12 hours before testing. Pulmonary function tests and evaluation of FeNO were assessed on the same day of clinical visit. Clinical assessment and adverse effects, serum IgE and ECP levels with pulmonary function tests, ACT (Quality Metric Incorp.) and FeNO concentrations were assessed during each outpatient visits. The latest version of severity of asthma score (SOA) was used to diagnose asthma severity (13) . FeNO was evaluated under the ATS/ERS guidelines (NObreath; Bedfont Scientific Ltd., Rochester, Kent, UK). Subjects first inhaled ambient air to near total lung capacity and then exhaled for 16 s at a constant flow rate through a mouthpiece into the device. Patients' daily medications, asthma severity, and control test scores were recorded (4, 14) . Serum samples were centrifuged at 3000 rpm for 10 minutes to separate them from cells. OX2 levels (Sino Biological Inc., Catalog Number: SEK10886) and IL-1β (Diaclone, Catalog No: 851.610.005) were counted in serum samples via enzyme-linked immunosorbent assay according to the manufacturer's guidance. Serum Hcy concentrations were measured using an Hcy assay kit (Roche). Serum IgE concentrations were quantified via fluoroenzyme immunoassay (FEIA) which uses an ImmunoCAP (Pharmacia, Uppsala, Sweden). All of the patients have high IgE levels. Cutoff value was 100 kU/L for total IgE concentration and 0.35 kU/L for specific IgE concentration for selected patients. Serum 25(OH)D concentrations were counted via a radioimmunoassay (Cobra Quantum, Packard, MN), and we categorized its concentration as sufficient (≥30 ng/mL), deficient (<20 ng/mL), or insufficient (20-30 ng/mL), based on previous suggestions (15) . The doubled measurements were recorded from devices.
All patients underwent skin prick tests (SPT) since they are first diagnosed because of our regular clinical algorithm which uses standardized latex extract and a complete allergens set which includes 35 common (such as pollen and mite) and food allergens (Allergopharma, Reinbek, Germany) ( Table 1) . Total IgE levels were also administered within the correlation of SPTs.
Treatment protocol
Patients were questioned so as to decide their treatment protocol for maintaining asthma diaries, and the use of total oral corticosteroid dose per month was recorded. Patients were also questioned to emergency unit visits for asthma exacerbation. They were also told, preferably, to go to our outpatient allergy clinic during working hours instead of going to emergency room outside the working hours, in order to keep the treatment under control. Best standard care was conducted following medications with inhaled salmeterol 50 mg bid, inhaled fluticasone 500 mg bid, and oral methyl prednisolone according to the suggestions from GINA. Omalizumab treatment was started patients at least 12 months according to GINA. Oral steroid doses were decreased if the patient clinical signs were stable. Oral steroid was reduced to 2 mg/week in the following weeks. Four of our patients used oral steroid, and we could stop them from using oral steroid by gradually reducing their medication.
Statistical Analysis
The data were presented as means ± SD. Data were analyzed by descriptive and inferential statistics using the SPSS 13.0 version (Statistical Package for the Social Sciences Inc.; Chicago, IL, USA). In comparison of groups, the Student t test was used according to the normality of distribution of the variables in dependent groups. Pearson correlation analysis was used for correlations between variables. p-value meant statistically significant when it was less than 0.05.
RESULTS
The general features and laboratory test results of the patients and control group are summarized in Table 2 . ACT score is shown in Fig-ure however, serum Hcy (mmol/mL) concentrations were statistically sig- Figure 3 with p<0.05. ECP is demonstrated in Figure 4 with p<0.05 and FeNO in Figure 5 with p<0.001. SOA is demonstrated in Figure 6 with p<0.001 and sCD200 in Figure 7 with p<0.0001. On the contrary, total IgE, ECP, FeNO, SOA, and sCD200 were all significantly decreased in the post-omalizumab group. However, IL-1β concentrations in the patients and control groups have no statistically significant variation which is demonstrated in Figure 8 . 
DISCUSSION
The major pathophysiological mechanisms of omalizumab treatment in patients with asthma are still being investigated by many groups, while some systematic reviews show that omalizumab has efficiency as an additional treatment option in allergic patients with asthma (16) . There is no knowledge about serum soluble biomarkers related to inflammation including Hcy, OX2, and 25(OH)D concentrations in asthmatics and their potency to guide a therapeutic approach by omalizumab. Our study showed that these are able to guide a therapeutic approach by omalizumab.
Cell membrane--connected OX2 and serum-soluble form of OX2 are novel immune-efficient molecules which have dual effects as a pro-inflammatory through its receptor and an immunomodulatory drug (8) . In a previous study, OX2 levels were altering owing to the clinical condition of patients that might be on account of playing the role of pathogenesis of autoimmune/inflammatory diseases (17, 18). Our observations on the patients seem to be supporting the role of OX2 as a pro-inflammatory molecule such as IL-1β (8, 19, 20) . Thus, the increased levels of OX2 seen in our study with active disease (Group 1A) presumably represent a manifestation of a homeostatic response directed to the control of inflammation. The diminished levels of OX2, seen in the post-omalizumab group, reflect the successful suppression of the inflammatory response. 25(OH)D which is a steroid hormone is approved to have immunomodulatory effects both in vitro and in vivo. Data from previous researches suggest that 25(OH)D has important effects on the inflammation of the respiratory tract and is a predictive marker for pulmonary function (9) . Nonetheless, it is scarcely unknown that whether this effect is on natural or adaptive immune system or is connected to cytokines. Its association with asthma severity in relation to different treatment modalities is also unknown (15, 19-21 ). Hence by our study, we investigated the serum 25(OH)D concentrations in patients with asthma with other inflammatory molecules in relation to omalizumab treatment. 25(OH)D studies were increased in the last decade, and many studies reported that its deficit is contrarily associated with BMI. We concluded that the increase in 25(OH)D might be due to a decreased use of systemic steroids with accomplished biological treatment modality (20) . The other probable explanation is, as reported earlier, the seasonal factors relating the vitamin D levels. It decreases from summer to winter (22) . In this study, we also had the samples from the patients during the highest pollination time in our region during May within the average temperature of 25°C with high humidity percentage as in mid-summer season in many other countries. This data however propose a new target to study, air pollination and seasonal effects.
Asthma is linked to eosinophils which are found in increased levels in our body. Elevated levels of ECP have been observed in asthmatics. Additionally, there is an association between increased ECP concentrations and asthma aggravation as a biomarker (23, 24) . We observed a correlation between ECP and FeNO and FeNO and age in the pretreatment group (Group IA) in our study.
The effect of IL-1β on asthma pathology was earlier defined and linked with inflammation (25) . Fascinatingly, Group IA has a positive correlation between IL-1β levels and SOA, while in Group IB, there is a negative correlation between IL-1β levels and FEV 1 . Conversely, there was no change in IL-1β levels between the groups and omalizumab had no effect on IL-1β levels. Controversial to prior studies showing a decrease on IL-1β levels in severe asthmatics, no change in the concentration might be caused in patients having asthma and shorter treatment periods (19, 20, 26) .
A few researches have pointed out that Hcy may lead to the advancement of atherosclerosis, which is an important risk factor of cardiovascular diseases. Nevertheless, mechanisms of endothelial dysfunction induced by Hcy are not yet exactly known. Also, Hcy has a pro-inflammatory property which was proven by studies. According to our results, we might speculate that it is an endothelial protection mechanism which might be together with an increase in IgE levels (27) .
After all, our study is the first one to investigate the significance of distinct levels of serum sCD200, 25(OH)D, and Hcy in allergic asthma patients. The correlation of these levels with clinical features was performed after the omalizumab treatment. As shown in our data and previous studies, clinical follow-up markers are extremely associated with increased levels of immunoregulatory functioning 25(OH)D and decreased levels of Hcy, OX2, and ECP (20) . Furthermore, the decrease in OX2 and Hcy serum levels and increase in 25(OH)D levels promote the probable mechanism of vascular endothelial protection. The increased 25(OH)D concentrations and decreased levels of ECP are reliable with the hypotheses that state these molecules play a significant part in reducing disease progression and pathology, respectively.
The number of research studies seems to be a small group. However, it is difficult to identify such large study groups when considering new biological treatments within the same clinical status. In addition, omalizumab treatment is not a cheap treatment option in our country due to the fact that a large number of patient series are needed.
In conclusion, these data recommend that the measurement of Hcy, 25(OH)D, and sCD200 might be a useful biomarker to get supplementary information about patients' inflammatory status to traditional clinical measures and this study might be done using more study groups because different groups might guide a way to an optimal therapeutic approach by omalizumab.
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